Clinical Trial Update: A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation [Phase 4]

View source ↗

Summary

A Phase 4 pilot study evaluating smart adherence technology to measure lumacaftor/ivacaftor adherence in cystic fibrosis patients homozygous for F508del; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 4 | Status: TERMINATED | Results posted: 2018-09-27